Literature DB >> 23463371

Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?

Belinda Gier1, Peter C Butler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23463371     DOI： 10.1001/jamainternmed.2013.3374

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  6 in total

1.  Incretin-based therapies: facing the realities of benefits versus side effects.

Authors:  Harold E Lebovitz
Journal:  Diabetes Technol Ther       Date:  2013-10-10       Impact factor: 6.118

Review 2.  The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?

Authors:  Ricardo Godinho; Cristina Mega; Edite Teixeira-de-Lemos; Eugénia Carvalho; Frederico Teixeira; Rosa Fernandes; Flávio Reis
Journal:  J Diabetes Res       Date:  2015-05-17       Impact factor: 4.011

3.  Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.

Authors:  Jean-Francois Gautier; Luc Martinez; Alfred Penfornis; Eveline Eschwège; Guillaume Charpentier; Benoît Huret; Suliya Madani; Pierre Gourdy
Journal:  Adv Ther       Date:  2015-09-30       Impact factor: 3.845

Review 4.  Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.

Authors:  Daniel J Drucker
Journal:  Diabetes       Date:  2013-07-01       Impact factor: 9.461

Review 5.  Diabetes and cancer: two diseases with obesity as a common risk factor.

Authors:  S K Garg; H Maurer; K Reed; R Selagamsetty
Journal:  Diabetes Obes Metab       Date:  2013-06-12       Impact factor: 6.577

6.  Lessons From LEADER - All-round Leadership.

Authors:  Sanjay Kalra
Journal:  Eur Endocrinol       Date:  2016-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.